

Resource Summary Report

Generated by PRECISE-TBI on Aug 9, 2026

APC anti-human CD3

RRID:AB_2562045

Type: Antibody

Proper Citation

BioLegend Cat# 300439, RRID:AB_2562045

Antibody Information

URL: http://antibodyregistry.org/AB_2562045

Proper Citation: BioLegend Cat# 300439, RRID:AB_2562045

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone UCHT1

Antibody ID: AB_2562045

Vendor: BioLegend

Catalog Number: 300439

Alternative Catalog Numbers: 300412, 300411, 300458

Record Creation Time: 20250820T040046+0000

Record Last Update: 20250820T174747+0000

Ratings and Alerts

No rating or validation information has been found for APC anti-human CD3.

No alerts have been found for APC anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Zheng D, et al. (2025) CD4+ anti-TGF- β CAR T cells and CD8+ conventional CAR T cells exhibit synergistic antitumor effects. Cell reports. Medicine, 6(3), 102020.

Barlow KA, et al. (2025) Design of orthogonal constant domain interfaces to aid proper heavy/light chain pairing of bispecific antibodies. mAbs, 17(1), 2479531.

Jeon SH, et al. (2025) Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(21), 4586.

Mitsuno K, et al. (2025) Selective JAK2 pathway inhibition enhances anti-leukemic functionality in CD19 CAR-T cells. Cancer immunology, immunotherapy : CII, 74(3), 79.

Kaufman B, et al. (2025) N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1. Molecular cancer, 24(1), 140.

Ishino T, et al. (2025) Immunopeptidomics combined with full-length transcriptomics uncovers diverse neoantigens. Cell reports, 45(1), 116781.

Sugita Y, et al. (2024) Candidate tumor-specific CD8+ T cell subsets identified in the malignant pleural effusion of advanced lung cancer patients by single-cell analysis. Oncoimmunology, 13(1), 2371556.

Swan GA, et al. (2024) A conserved element in the first intron of Cd4 has a lineage specific, TCR signal-responsive, canonical enhancer function that matches the timing of cell surface CD4 upregulation required to prevent lineage choice error. Frontiers in immunology, 15, 1469402.

Oyer JL, et al. (2022) Cryopreserved PM21-Particle-Expanded Natural Killer Cells Maintain Cytotoxicity and Effector Functions In Vitro and In Vivo. Frontiers in immunology, 13, 861681.

Moquin-Beaudry G, et al. (2022) Autologous humanized mouse models of iPSC-derived tumors enable characterization and modulation of cancer-immune cell interactions. Cell reports methods, 2(1), 100153.

Le J, et al. (2020) Single-Cell RNA-Seq Mapping of Human Thymopoiesis Reveals Lineage Specification Trajectories and a Commitment Spectrum in T Cell Development. *Immunity*, 52(6), 1105.

Katsuyama E, et al. (2020) The CD38/NAD/SIRTUIN1/EZH2 Axis Mitigates Cytotoxic CD8 T Cell Function and Identifies Patients with SLE Prone to Infections. *Cell reports*, 30(1), 112.

Sibener LV, et al. (2018) Isolation of a Structural Mechanism for Uncoupling T Cell Receptor Signaling from Peptide-MHC Binding. *Cell*, 174(3), 672.